Cargando…
Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk receive systemic therapy with the primary tumour (primary) in place, with the option of deferred cytoreductive nephrectomy (CN) i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738899/ https://www.ncbi.nlm.nih.gov/pubmed/35024632 http://dx.doi.org/10.1016/j.euros.2021.11.003 |
_version_ | 1784629003291721728 |
---|---|
author | Meerveld-Eggink, Aafke Graafland, Niels Wilgenhof, Sofie Van Thienen, Johannes V. Lalezari, Ferry Grant, Michael Szabados, Bernadett Abu-Ghanem, Yasmin Kuusk, Teele Boleti, Ekaterini Blank, Christian U. Haanen, John B.A.G. Powles, Thomas Bex, Axel |
author_facet | Meerveld-Eggink, Aafke Graafland, Niels Wilgenhof, Sofie Van Thienen, Johannes V. Lalezari, Ferry Grant, Michael Szabados, Bernadett Abu-Ghanem, Yasmin Kuusk, Teele Boleti, Ekaterini Blank, Christian U. Haanen, John B.A.G. Powles, Thomas Bex, Axel |
author_sort | Meerveld-Eggink, Aafke |
collection | PubMed |
description | Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk receive systemic therapy with the primary tumour (primary) in place, with the option of deferred cytoreductive nephrectomy (CN) in responding patients. We retrospectively analysed the safety and efficacy of first-line nivolumab/ipilimumab in 71 primary mRCC patients (42.3% IMDC poor risk; 43.6% with more than three metastatic sites). The baseline mean primary diameter was 9.3 cm and median follow-up was 11.5 mo. Of 69 patients with at least one follow-up computed tomography scan, 23 (33.3 %) had a partial response (PR) of the primary after a median of 4.8 mo, which was associated with a 91.3% overall response rate at metastatic sites (MSs) and absence of progressive disease, irrespective of the IMDC risk. The complete response (CR) rate at MSs (n = 7 [10.1%]) is similar to the CR rate in CheckMate 214. Thirteen deferred CNs were performed (18.8%) after a median of 13 mo, rendering four patients disease free. Only 4.3% of primaries progressed; grade 3–4 immune-related adverse events occurred in 31.9%. Irrespective of the IMDC risk, patients with a PR in the primary had a 1-yr overall survival rate of 89% versus 67% in those without (p = 0.012). PATIENT SUMMARY: Patients with metastatic kidney cancer receiving immunotherapy with nivolumab and ipilimumab had superior response at metastatic sites and better survival irrespective of International Metastatic RCC Database Consortium (IMDC) risk. |
format | Online Article Text |
id | pubmed-8738899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87388992022-01-11 Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment Meerveld-Eggink, Aafke Graafland, Niels Wilgenhof, Sofie Van Thienen, Johannes V. Lalezari, Ferry Grant, Michael Szabados, Bernadett Abu-Ghanem, Yasmin Kuusk, Teele Boleti, Ekaterini Blank, Christian U. Haanen, John B.A.G. Powles, Thomas Bex, Axel Eur Urol Open Sci Brief Correspondence Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk receive systemic therapy with the primary tumour (primary) in place, with the option of deferred cytoreductive nephrectomy (CN) in responding patients. We retrospectively analysed the safety and efficacy of first-line nivolumab/ipilimumab in 71 primary mRCC patients (42.3% IMDC poor risk; 43.6% with more than three metastatic sites). The baseline mean primary diameter was 9.3 cm and median follow-up was 11.5 mo. Of 69 patients with at least one follow-up computed tomography scan, 23 (33.3 %) had a partial response (PR) of the primary after a median of 4.8 mo, which was associated with a 91.3% overall response rate at metastatic sites (MSs) and absence of progressive disease, irrespective of the IMDC risk. The complete response (CR) rate at MSs (n = 7 [10.1%]) is similar to the CR rate in CheckMate 214. Thirteen deferred CNs were performed (18.8%) after a median of 13 mo, rendering four patients disease free. Only 4.3% of primaries progressed; grade 3–4 immune-related adverse events occurred in 31.9%. Irrespective of the IMDC risk, patients with a PR in the primary had a 1-yr overall survival rate of 89% versus 67% in those without (p = 0.012). PATIENT SUMMARY: Patients with metastatic kidney cancer receiving immunotherapy with nivolumab and ipilimumab had superior response at metastatic sites and better survival irrespective of International Metastatic RCC Database Consortium (IMDC) risk. Elsevier 2022-01-03 /pmc/articles/PMC8738899/ /pubmed/35024632 http://dx.doi.org/10.1016/j.euros.2021.11.003 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Correspondence Meerveld-Eggink, Aafke Graafland, Niels Wilgenhof, Sofie Van Thienen, Johannes V. Lalezari, Ferry Grant, Michael Szabados, Bernadett Abu-Ghanem, Yasmin Kuusk, Teele Boleti, Ekaterini Blank, Christian U. Haanen, John B.A.G. Powles, Thomas Bex, Axel Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title_full | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title_fullStr | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title_full_unstemmed | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title_short | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment |
title_sort | primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment |
topic | Brief Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738899/ https://www.ncbi.nlm.nih.gov/pubmed/35024632 http://dx.doi.org/10.1016/j.euros.2021.11.003 |
work_keys_str_mv | AT meerveldegginkaafke primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT graaflandniels primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT wilgenhofsofie primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT vanthienenjohannesv primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT lalezariferry primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT grantmichael primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT szabadosbernadett primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT abughanemyasmin primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT kuuskteele primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT boletiekaterini primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT blankchristianu primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT haanenjohnbag primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT powlesthomas primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment AT bexaxel primaryrenaltumourresponseinpatientstreatedwithnivolumabandipilimumabformetastaticrenalcellcarcinomarealworlddataassessment |